Research ExplorerPublicationsEndocrine Treatment with 2 Years of Tamoxifen versus 2 Years...

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Standard

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. / Schochter, Fabienne; Rack, Brigitte; Tzschaschel, Marie; Polasik, Arkadius; Andergassen, Ulrich; Trapp, Elisabeth; Alunni-Fabbroni, Marianna; Schneeweiss, Andreas; Müller, Volkmar; Pantel, Klaus; Gade, Jörg; Lorenz, Ralf; Rezai, Mahdi; Tesch, Hans; Soeling, Ulrike; Fehm, Tanja; Mahner, Sven; Schindlbeck, Christian; Lichtenegger, Werner; Beckmann, Matthias W; Fasching, Peter A; Janni, Wolfgang; Friedl, Thomas W P; SUCCESS Study Group.

In: ONCOL RES TREAT, Vol. 41, No. 3, 2018, p. 93-98.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schochter, F, Rack, B, Tzschaschel, M, Polasik, A, Andergassen, U, Trapp, E, Alunni-Fabbroni, M, Schneeweiss, A, Müller, V, Pantel, K, Gade, J, Lorenz, R, Rezai, M, Tesch, H, Soeling, U, Fehm, T, Mahner, S, Schindlbeck, C, Lichtenegger, W, Beckmann, MW, Fasching, PA, Janni, W, Friedl, TWP & SUCCESS Study Group 2018, 'Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study', ONCOL RES TREAT, vol. 41, no. 3, pp. 93-98. https://doi.org/10.1159/000485566

APA

Schochter, F., Rack, B., Tzschaschel, M., Polasik, A., Andergassen, U., Trapp, E., Alunni-Fabbroni, M., Schneeweiss, A., Müller, V., Pantel, K., Gade, J., Lorenz, R., Rezai, M., Tesch, H., Soeling, U., Fehm, T., Mahner, S., Schindlbeck, C., Lichtenegger, W., ... SUCCESS Study Group (2018). Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. ONCOL RES TREAT, 41(3), 93-98. https://doi.org/10.1159/000485566

Vancouver

Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E et al. Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. ONCOL RES TREAT. 2018;41(3):93-98. https://doi.org/10.1159/000485566

Bibtex

@article{7a2789c7b724429eb8dc98632f4b5d00,
title = "Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study",
abstract = "BACKGROUND: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.PATIENTS AND METHODS: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch{\textregistered} System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.RESULTS: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups.CONCLUSION: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.",
keywords = "Journal Article",
author = "Fabienne Schochter and Brigitte Rack and Marie Tzschaschel and Arkadius Polasik and Ulrich Andergassen and Elisabeth Trapp and Marianna Alunni-Fabbroni and Andreas Schneeweiss and Volkmar M{\"u}ller and Klaus Pantel and J{\"o}rg Gade and Ralf Lorenz and Mahdi Rezai and Hans Tesch and Ulrike Soeling and Tanja Fehm and Sven Mahner and Christian Schindlbeck and Werner Lichtenegger and Beckmann, {Matthias W} and Fasching, {Peter A} and Wolfgang Janni and Friedl, {Thomas W P} and {SUCCESS Study Group}",
note = "{\textcopyright} 2018 S. Karger GmbH, Freiburg.",
year = "2018",
doi = "10.1159/000485566",
language = "English",
volume = "41",
pages = "93--98",
journal = "ONCOL RES TREAT",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

AU - Schochter, Fabienne

AU - Rack, Brigitte

AU - Tzschaschel, Marie

AU - Polasik, Arkadius

AU - Andergassen, Ulrich

AU - Trapp, Elisabeth

AU - Alunni-Fabbroni, Marianna

AU - Schneeweiss, Andreas

AU - Müller, Volkmar

AU - Pantel, Klaus

AU - Gade, Jörg

AU - Lorenz, Ralf

AU - Rezai, Mahdi

AU - Tesch, Hans

AU - Soeling, Ulrike

AU - Fehm, Tanja

AU - Mahner, Sven

AU - Schindlbeck, Christian

AU - Lichtenegger, Werner

AU - Beckmann, Matthias W

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Friedl, Thomas W P

AU - SUCCESS Study Group

N1 - © 2018 S. Karger GmbH, Freiburg.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.PATIENTS AND METHODS: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.RESULTS: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups.CONCLUSION: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.

AB - BACKGROUND: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.PATIENTS AND METHODS: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.RESULTS: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups.CONCLUSION: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.

KW - Journal Article

U2 - 10.1159/000485566

DO - 10.1159/000485566

M3 - SCORING: Journal article

C2 - 29490302

VL - 41

SP - 93

EP - 98

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 3

ER -